Regen BioPharma Inc

Chart & Performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div Yield, %

—

Shrs. gr., 5y

90.41%

Rev. gr., 5y

16.55%

Revenues

237k

+0.00%

Net income

-1m

L+90.79%

CFO

-384k

L-44.66%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Profile

Regen BioPharma, Inc. is a company dedicated to advancing regenerative medicine within the United States. It actively researches and identifies small molecule compounds designed to modulate the NR2F6 gene. This modulation is strategically aimed at activating immune cells for oncology treatments and suppressing them for autoimmune conditions. Its therapeutic pipeline and product development are currently in their initial phases. Established in 2012, the firm operates from its headquarters in La Mesa, California.

URL

https://regenbiopharmainc.com/

IPO date

Sep 03, 2014

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title in thousands, except ratios and share amounts	2025‑09	2024‑09	2023‑09	2022‑09	2021‑09	2020‑09	2019‑09	2018‑09	2017‑09	2016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT